Featured Insights
2026 EXL AI Enterprise study for Life Sciences
Transforming healthcare through connected experiences
Connect, govern, and activate healthcare data for AI
Where we operate
How EXL drives life sciences innovation
On small screens, swipe horizontally or use the left and right arrow keys to browse solutions.
"$20M+ annual uplift from HEOR and market-access studies."
"60–80% less manual reconciliation, 100% audit lineage."
"50–70% faster AI-ready data across the value chain."
Get instant benefits of working with EXL
"First value in an 8–12 week POC, 2–5× pilot ROI."
"Proven across pharma, biotech and medtech - 25+ years’ delivery."
"Empowered teams with EXLdata.ai agents and GenAI accelerators."
Recognized by leading analysts
View allTeaming with <br><span class="wm-orange-text">top partners</span>
VIEW ALLFrequently asked 
questions
We unify expert-curated multi-omics, assay and literature into a knowledge graph for target ID.
We map EDC, lab, imaging and eCOA to CDISC with expert coding fewer queries, cleaner lock.
We author eCTD dossiers, SOP-grounded, source-traceable and expert-reviewed.
Clinician-adjudicated case intake and MedDRA coding surface signals earlier across literature and RWD.
We build a trusted HCP, payer and patient 360 for next-best-action, MLR and HEOR.
We connect demand, batch, quality and cold-chain data to sharpen forecasting and speed CAPA, GMP-fit.
Domain experts red-team, evaluate and ground-truth models; human-in-the-loop, full audit lineage for GxP, 21 CFR Part 11, ALCOA+.
Let's <span class='o_highlight'>solve together</span>
Combine human ingenuity with advanced AI to discover faster, keep patients on therapy, and grow with confidence.
Talk to an expert